Indivior FY2025 EPS Estimate Decreased by Northland Capmk

Indivior PLC (NASDAQ:INDV) – Investment analysts at Northland Capmk dropped their FY2025 earnings estimates for Indivior in a report released on Thursday, February 20th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.90 for the year, down from their previous forecast of $1.00. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

A number of other equities research analysts have also commented on the company. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company.

Indivior Stock Up 0.1 %

Shares of Indivior stock opened at $8.26 on Monday. Indivior has a 12 month low of $7.33 and a 12 month high of $23.22. The stock has a market cap of $1.14 billion, a PE ratio of -23.60 and a beta of 0.73. The business has a fifty day simple moving average of $11.37 and a 200-day simple moving average of $10.77.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The firm had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million.

Institutional Trading of Indivior

A number of institutional investors have recently bought and sold shares of INDV. VELA Investment Management LLC raised its stake in shares of Indivior by 722.9% during the 3rd quarter. VELA Investment Management LLC now owns 123,435 shares of the company’s stock worth $1,212,000 after purchasing an additional 108,435 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Indivior in the fourth quarter worth approximately $359,000. Stifel Financial Corp bought a new position in Indivior during the third quarter valued at approximately $100,000. AlphaCentric Advisors LLC acquired a new stake in Indivior in the third quarter valued at approximately $2,364,000. Finally, Clark Estates Inc. NY bought a new stake in Indivior in the third quarter worth approximately $2,477,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.